Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Bank of America Corp DE boosted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 938.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 170,543 shares of the biotechnology company’s stock after acquiring an additional 154,127 shares during the period. Bank of America Corp DE owned 0.38% of Capricor Therapeutics worth $2,353,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. raised its position in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund raised its position in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

CAPR stock opened at $10.21 on Tuesday. The firm has a fifty day moving average price of $10.15 and a 200 day moving average price of $13.05. The firm has a market cap of $466.36 million, a PE ratio of -9.63 and a beta of 0.85. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same period in the previous year, the firm earned ($0.31) earnings per share. On average, equities analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CAPR shares. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Roth Capital initiated coverage on shares of Capricor Therapeutics in a report on Tuesday, May 20th. They issued a “buy” rating and a $31.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.